Idelalisib Research Program Open for Lymphoma

Andre K.D. Liem, MD

Idelalisib (eye-del-a-lis-ib) (GS 1101, GS-1101) (formerly CAL-101) is an oral inhibitor of PI3K-delta. The PI3K pathway is an important for many cellular functions such as growth control. PI3K delta is critical for activation, proliferation and survival of B lymphocytes. In many B cell malignancies the PI3K signalling is hyperactive causing increased proliferation, survival and trafficking to lymphoid tissue. Idelalisib has shown to inhibit proliferation and induce apoptosis (cell death) in many B cell malignancies in pre-clinical and clinical studies.

We have opened two clinical trials for indolent lymphoma:

1. Rituximab with or without Idelalisib: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (for more info see clinicaltrials.gov click here)
2. Rituximab and bendamustine with or without Idelalisib: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas (for more info see clinicaltrials.gov click here)
   

This target group is patient with low grade lymphoma who have received treatment with rituximab (with or without chemotherapy, but have a recurrence. Both studies have  three treatment arms. Two arms have contain idelalisib and on arm has placebo. Everybody will get treatment with rituximab or rituxumab and bendamustine depending on the study.

These research trials are open at our Long Beach (Elm and Worsham), Huntington Beach and Irvine locations.

For more information call Irene at 562-590-0345

---